today announced the presentation of additional preclinical data supporting the use of novel compounds, based on the company's texaphyrin technology, to enhance visualization of vulnerable atherosclerotic plaque
, which is widely believed to be a major cause of cardiovascular disease (CVD).
is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque
deposits and to safely improve lipid profiles in humans.
Pregnancy associated plasma protein-A (PAPP-A) is not a marker of the vulnerable atherosclerotic plaque
They found that several bacteria were found in the atherosclerotic plaques
and, primarily, the mouth, but also the gut, of the same patient and that the bacteria Pseudomonas luteola and Chlamydia pneumoniae were present in all atherosclerotic plaques
Although the mean atherosclerotic plaque
burden did increase with the 10-year Framingham risk, the correlation between [the FRS] and plaque was fair," Dr.
Coronary artery calcification (CAC) is present in atherosclerotic plaque
and is usually the tip of the atherosclerotic iceberg.
Volcano Corporation today announced the commercial launch of its patented VH(TM) IVUS system -- the first technology to enable real time (in the cardiac catheterization lab) compositional assessment of atherosclerotic plaques
in coronary arteries.
6) It is clear that a hemodynamically nonsignificant coronary atherosclerotic plaque
can rupture and produce a cardiac event long before it produces significant lumen narrowing and angina pectoris, if the above-mentioned plaque characteristics are met.
pneumoniae heat shock protein (HSP-60) can activate both macrophage tumor necrosis factor-alpha and expression of matrix-degrading proteinases that may weaken atherosclerotic plaques
, rendering them susceptible to rupture and hence thrombosis.
sPLA2 is in a family of pro-inflammatory enzymes linked to the formation and destabilization of atherosclerotic plaques
OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque
and to improve lipid profiles in humans, today announced that its Russian licensing partner CardioNova has received written notification of approval of the Phase 1 protocol in its Investigational New Drug (IND) application with the Ministry of Healthcare of the Russian Federation (Minzdrav).
C-reactive protein levels appear to be a poor predictor of atherosclerotic plaque
burden, reported Dr.